These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29298888)

  • 1. Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors.
    Abbink P; Kirilova M; Boyd M; Mercado N; Li Z; Nityanandam R; Nanayakkara O; Peterson R; Larocca RA; Aid M; Tartaglia L; Mutetwa T; Blass E; Jetton D; Maxfield LF; Borducchi EN; Badamchi-Zadeh A; Handley S; Zhao G; Virgin HW; Havenga MJ; Barouch DH
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29298888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors.
    Abbink P; Maxfield LF; Ng'ang'a D; Borducchi EN; Iampietro MJ; Bricault CA; Teigler JE; Blackmore S; Parenteau L; Wagh K; Handley SA; Zhao G; Virgin HW; Korber B; Barouch DH
    J Virol; 2015 Feb; 89(3):1512-22. PubMed ID: 25410856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D.
    Abbink P; Lemckert AA; Ewald BA; Lynch DM; Denholtz M; Smits S; Holterman L; Damen I; Vogels R; Thorner AR; O'Brien KL; Carville A; Mansfield KG; Goudsmit J; Havenga MJ; Barouch DH
    J Virol; 2007 May; 81(9):4654-63. PubMed ID: 17329340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.
    Tostanoski LH; Gralinski LE; Martinez DR; Schaefer A; Mahrokhian SH; Li Z; Nampanya F; Wan H; Yu J; Chang A; Liu J; McMahan K; Ventura JD; Dinnon KH; Leist SR; Baric RS; Barouch DH
    J Virol; 2021 Nov; 95(23):e0097421. PubMed ID: 34523968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
    Roberts DM; Nanda A; Havenga MJ; Abbink P; Lynch DM; Ewald BA; Liu J; Thorner AR; Swanson PE; Gorgone DA; Lifton MA; Lemckert AA; Holterman L; Chen B; Dilraj A; Carville A; Mansfield KG; Goudsmit J; Barouch DH
    Nature; 2006 May; 441(7090):239-43. PubMed ID: 16625206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors.
    Iampietro MJ; Larocca RA; Provine NM; Abbink P; Kang ZH; Bricault CA; Barouch DH
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29563285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques.
    Capone S; Meola A; Ercole BB; Vitelli A; Pezzanera M; Ruggeri L; Davies ME; Tafi R; Santini C; Luzzago A; Fu TM; Bett A; Colloca S; Cortese R; Nicosia A; Folgori A
    J Virol; 2006 Feb; 80(4):1688-99. PubMed ID: 16439526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.
    Dicks MD; Spencer AJ; Edwards NJ; Wadell G; Bojang K; Gilbert SC; Hill AV; Cottingham MG
    PLoS One; 2012; 7(7):e40385. PubMed ID: 22808149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD46-mediated transduction of a species D adenovirus vaccine improves mucosal vaccine efficacy.
    Camacho ZT; Turner MA; Barry MA; Weaver EA
    Hum Gene Ther; 2014 Apr; 25(4):364-74. PubMed ID: 24635714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys.
    Nanda A; Lynch DM; Goudsmit J; Lemckert AA; Ewald BA; Sumida SM; Truitt DM; Abbink P; Kishko MG; Gorgone DA; Lifton MA; Shen L; Carville A; Mansfield KG; Havenga MJ; Barouch DH
    J Virol; 2005 Nov; 79(22):14161-8. PubMed ID: 16254351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors.
    McCoy K; Tatsis N; Korioth-Schmitz B; Lasaro MO; Hensley SE; Lin SW; Li Y; Giles-Davis W; Cun A; Zhou D; Xiang Z; Letvin NL; Ertl HC
    J Virol; 2007 Jun; 81(12):6594-604. PubMed ID: 17428852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity.
    Hashimoto M; Boyer JL; Hackett NR; Wilson JM; Crystal RG
    Infect Immun; 2005 Oct; 73(10):6885-91. PubMed ID: 16177368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two Novel Adenovirus Vectors Mediated Differential Antibody Responses via Interferon-α and Natural Killer Cells.
    Zou P; Zhang P; Deng Q; Wang C; Luo S; Zhang L; Li C; Li T
    Microbiol Spectr; 2023 Aug; 11(4):e0088023. PubMed ID: 37347197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity.
    Ophorst OJ; Kostense S; Goudsmit J; De Swart RL; Verhaagh S; Zakhartchouk A; Van Meijer M; Sprangers M; Van Amerongen G; Yüksel S; Osterhaus AD; Havenga MJ
    Vaccine; 2004 Aug; 22(23-24):3035-44. PubMed ID: 15297053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity.
    Thorner AR; Lemckert AA; Goudsmit J; Lynch DM; Ewald BA; Denholtz M; Havenga MJ; Barouch DH
    J Virol; 2006 Dec; 80(24):12009-16. PubMed ID: 17035318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors.
    Paris R; Kuschner RA; Binn L; Thomas SJ; Colloca S; Nicosia A; Cortese R; Bailer RT; Sullivan N; Koup RA
    Clin Vaccine Immunol; 2014 May; 21(5):783-6. PubMed ID: 24623627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenoviruses as vaccine vectors.
    Tatsis N; Ertl HC
    Mol Ther; 2004 Oct; 10(4):616-29. PubMed ID: 15451446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines.
    Crosby CM; Nehete P; Sastry KJ; Barry MA
    J Virol; 2015 Jan; 89(1):669-75. PubMed ID: 25355873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased Vector Gene Expression from E2b Gene-Deleted Adenovirus Serotype 5 Vaccines Intensifies Proinflammatory Immune Responses.
    Quiroga D; Aldhamen YA; Godbehere S; Harding L; Amalfitano A
    Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28381403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors.
    Roy S; Gao G; Lu Y; Zhou X; Lock M; Calcedo R; Wilson JM
    Hum Gene Ther; 2004 May; 15(5):519-30. PubMed ID: 15144581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.